Biotechnology News and Research

RSS

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

London Genetics enters an intensive partnering programme

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September.

31 Oct 2009

Four abstracts on RSV and influenza prevention in pediatric health to be presented

MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.

31 Oct 2009

Exposure to mercury-based preservative in vaccines is minimal, says researchers

The injectable, multi-dose H1N1 vaccine contains the mercury-based preservative thimerosol to reduce risks of bacterial contamination. The presence of thimerosol has once again raised concerns whether there are risks posed to children when the tiny amount of mercury contained in thimerosol is included in a vaccine.

31 Oct 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

CCBR-SYNARC to expand its Electronic Data Capture capabilities for use in imaging clinical trials

CCBR-SYNARC, the world's leading provider of medical image analysis, biochemical marker, and clinical research center services to the pharmaceutical and biotechnology industries, announced the expansion of its Electronic Data Capture ("EDC") capabilities for use in imaging clinical trials.

30 Oct 2009

Trusted Process thought leaders at INC Research named winners at the 2009 Clinical Research Excellence Awards

INC Research®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, is pleased to announce that Trusted Process® thought leaders at INC Research were named winners at the 2009 Clinical Research Excellence Awards in London on October 20.

30 Oct 2009

Updated results from Oncolytics Biotech's Phase II study of REOLYSIN presented at CTOS meeting

Oncolytics Biotech Inc. announced that a poster presentation covering updated results of a Phase II study of REOLYSIN(R) administered intravenously to patients with sarcomas metastatic to the lung will be presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting being held in Miami Beach, Florida on November 6th, 2009.

30 Oct 2009

Monash University physiologist honored with Life Scientist of the Year award

A Monash University physiologist, whose research into weight management, obesity and diabetes has led to significant medical breakthroughs and drug design, has been awarded one of the nation's top research honours.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

The La Jolla Institute for Allergy & Immunology, an international leader in immunology research and San Diego's only research institute focused solely on immune-mediated diseases, today will dedicate its new Elam Discovery Wall and Type 1 Diabetes Center, which will focus on research into novel immunological-focused approaches to type 1 diabetes.

30 Oct 2009

2009 Schering-Plough Excellence Award for WuXi PharmaTech

WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company, with operations in China and the United States, today announced that it had received the 2009 Excellence Award from Schering-Plough.

30 Oct 2009

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY’s midkine patent portfolio for the development of novel lung cancer diagnostics.

30 Oct 2009

Third-quarter fiscal 2009 results announced by Adolor

Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.

29 Oct 2009

ZyGEM signs an agreement with VERITAS Japan to distribute DNA extraction products to the Japanese market

ZyGEM Corp. Ltd., a provider of innovative enzyme-based products for DNA extraction and other life sciences applications, today announced it has entered into an exclusive agreement with VERITAS Japan to distribute ZyGEM's DNA extraction products to the Japanese market.

29 Oct 2009

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.

29 Oct 2009

Third quarter 2009 financial results announced by United Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2009.

29 Oct 2009

Biotechnology News and Research

Amgen publishes Phase 3 study results of Aranesp

London Genetics enters an intensive partnering programme

Four abstracts on RSV and influenza prevention in pediatric health to be presented

Exposure to mercury-based preservative in vaccines is minimal, says researchers

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

sanofi-aventis reports financial results for the third quarter of 2009

CCBR-SYNARC to expand its Electronic Data Capture capabilities for use in imaging clinical trials

Trusted Process thought leaders at INC Research named winners at the 2009 Clinical Research Excellence Awards

Updated results from Oncolytics Biotech's Phase II study of REOLYSIN presented at CTOS meeting

Monash University physiologist honored with Life Scientist of the Year award

New state-of-the-art biotechnology center opened on the West Coast

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

2009 Schering-Plough Excellence Award for WuXi PharmaTech

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Third-quarter fiscal 2009 results announced by Adolor

ZyGEM signs an agreement with VERITAS Japan to distribute DNA extraction products to the Japanese market

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

Third-quarter 2009 financial results of Antigenics announced

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

Third quarter 2009 financial results announced by United Therapeutics

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News